Lactobacillus rhamnosus GG pour Antibiotic-Associated Diarrhea (AAD)
A Preuves Plusieurs grands essais cliniques montrent de manière constante des bénéfices significatifs.Meta-analyses demonstrate LGG reduces AAD incidence by 42-49%. Most effective when started within 48 hours of antibiotic initiation and continued 7 days after completion.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dlactobacillus\u002Drhamnosus\u002Dgg\u0026condition\u003Dantibiotic\u002Dassociated\u002Ddiarrhea';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
A
En conclusion
Meta-analyses demonstrate LGG reduces AAD incidence by 42-49%. Most effective when started within 48 hours of antibiotic initiation and continued 7 days after completion.
Key Study Findings
Observational Study
n=279
Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care …
Dose: None
vs: None
Outcome: Probiotic prescribing habits of Italian PCPs
Effet: L. rhamnosus GG used by 91.8%
None
Population: Italian primary care pediatricians
Other
Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and …
Dose: None
vs: None
Outcome: Clinical guideline recommendations for pediatric GI
Effet: None
None
Population: Pediatric patients with GI disorders
Controlled Clinical Trial
n=24
2 weeks
Protective Effect of Probiotics on Cardiac Damage in Experimental Sepsis Model Induced by Lipopolysaccharide in …
Dose: 10^9 CFU/day for 14 days
vs: LPS-only group (no probiotics)
Outcome: Cardiac damage markers (CK-MB, cTn-I, cytokines)
Effet: None
p<0.05 to <0.001
Population: Male Wistar albino rats with LPS-induced sepsis
Review
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Dose: None
vs: None
Outcome: None
Effet: None
None
Population: Pediatric population
Randomized Controlled Trial
Double-blind
A Multi-Hospital Comparative Study on the Efficacy of Probiotics Versus Placebo in Preventing Antibiotic-Associated Diarrhea …
Dose: Probiotics (multi-strain)
vs: Placebo
Outcome: Antibiotic-associated diarrhea incidence
Effet: None
None
Population: Adult patients receiving antibiotics
Review
Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review.
Dose: S. boulardii CNCM I-745
vs: Placebo or standard care
Outcome: AAD prevention and pediatric gastroenteritis
Effet: None
None
Population: AAD and gastroenteritis patients (review)
Key Statistics
20
Études
4000
Participants
↑
Positive
A
Note
Referenced Papers
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Review
Journal of gastroenterology …
2025
10 citations
Medicina (Kaunas, Lithuania)
2025
1 citations
Antibiotics (Basel, Switzerland)
2025
Boletin medico del …
2025
Cureus
2024
1 citations
Cureus
2023
19 citations
Archivos argentinos de …
2022
23 citations
Canadian journal of …
2022
6 citations
International journal of …
2020
32 citations
Pediatric gastroenterology, hepatology …
2020
20 citations
Pharmacological research
2018
132 citations
A practical guide for probiotics applied to the case of antibiotic-associated diarrhea in The Netherlands.
Meta-Analysis
BMC gastroenterology
2018
80 citations
United European gastroenterology …
2018
66 citations
Probiotics and antimicrobial …
2018
26 citations
World journal of …
2017
68 citations
Journal of pediatric …
2016
233 citations
Digestive diseases (Basel, …
2016
37 citations
The use of probiotics in pediatric gastroenterology: a review of the literature and recommendations by Latin-American experts.
Systematic Review
Paediatric drugs
2015
122 citations
Journal of clinical …
2015
35 citations
Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children.
Review
Nutrition in clinical …
2015
31 citations
Nutricion hospitalaria
2015
5 citations
Medycyna wieku rozwojowego
2012
1 citations
Current opinion in …
2009
82 citations
Advances in biochemical …
2008
535 citations
The Journal of …
2007
265 citations
The American journal …
2006
918 citations
Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea.
Review
Journal of clinical …
2006
112 citations
Inflammation
2002
37 citations
The American journal …
2001
648 citations
Inflammation
2001
101 citations
The Journal of …
1999
559 citations
Pediatrics
1999
462 citations
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Posologies couramment utilisées
- general:
- 10-20 billion CFU/day
- ibssupport:
- 10 billion CFU/day for 4-8 weeks
- aadprevention:
- 10-20 billion CFU/day (start with antibiotic, continue 7 days after)
Limite supérieure : Generally well-tolerated up to 40 billion CFU/day in clinical trials
Posologies étudiées dans la recherche
| Posologie | Durée | Effet | N |
|---|---|---|---|
| None | -- | Mixed | 279 |
| None | -- | Positive | -- |
| 10^9 CFU/day for 14 days | 2 weeks | Positive | 24 |
| None | -- | Mixed | -- |
| Probiotics (multi-strain) | -- | Positive | -- |
| S. boulardii CNCM I-745 | -- | Positive | -- |
| None | -- | Positive | -- |
| Twice daily | -- | Neutral | 2650 |
Moment optimal de prise : On an empty stomach or 30 minutes before meals for optimal survival
Safety & Side Effects
Effets indésirables signalés
- ⚠ Mild gas and bloating during initial use (usually resolves in 1-2 weeks)
- ⚠ Rare reports of bacteremia in severely immunocompromised individuals
- ⚠ Occasional loose stools during adjustment period
- ⚠ Very rare: systemic infection in critically ill patients with central venous catheters
Interactions connues
- ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- ● Immunosuppressants (theoretical risk of infection in immunocompromised patients)
- ● Antifungals (no known interaction but may affect gut flora balance)
Apport maximal tolérable : Generally well-tolerated up to 40 billion CFU/day in clinical trials
Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.
Frequently Asked Questions
Does Lactobacillus rhamnosus GG help with Antibiotic-Associated Diarrhea (AAD)?
Based on 20 studies with 4,000 participants, there is strong evidence from multiple clinical trials that Lactobacillus rhamnosus GG may support Antibiotic-Associated Diarrhea (AAD) management. Our evidence grade is A (Strong Evidence).
How much Lactobacillus rhamnosus GG should I take for Antibiotic-Associated Diarrhea (AAD)?
Studies have used various dosages. A commonly studied range is 10-20 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus rhamnosus GG?
Reported side effects may include Mild gas and bloating during initial use (usually resolves in 1-2 weeks), Rare reports of bacteremia in severely immunocompromised individuals, Occasional loose stools during adjustment period, Very rare: systemic infection in critically ill patients with central venous catheters. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus rhamnosus GG and Antibiotic-Associated Diarrhea (AAD)?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 20 peer-reviewed studies with 4,000 total participants. The overall direction of effect is positive.
Related Evidence
Autres ingrédients pour Antibiotic-Associated Diarrhea (AAD)
Lactobacillus rhamnosus GG pour d'autres pathologies
References
- [1] Kok-Ann Gwee et al.. J Gastroenterol Hepatol. 2025. The evidence for probiotics in the treatment of digestive disorders in the pediatric population. doi:10.1111/jgh.16809 PubMed
- [2] Necip Gökhan Taş et al.. Medicina (Kaunas). 2025. Protective Effect of Probiotics on Cardiac Damage in Experimental Sepsis Model Induced by Lipopolysaccharide in Rats. doi:10.3390/medicina61040589 PubMed
- [3] Giacomo Biasucci et al.. Antibiotics (Basel). 2025. Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care Pediatricians. doi:10.3390/antibiotics14060577 PubMed
- [4] Sylvia Cruchet et al.. Bol Med Hosp Infant Mex. 2025. Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and nutrition: probiotics chapter. doi:10.24875/BMHIM.M25000043 PubMed
- [5] Jamal Shah et al.. Cureus. 2024. A Multi-Hospital Comparative Study on the Efficacy of Probiotics Versus Placebo in Preventing Antibiotic-Associated Diarrhea in Adult Patients. doi:10.7759/cureus.70881 PubMed
- [6] Sarath Gopalan et al.. Cureus. 2023. Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review. doi:10.7759/cureus.46314 PubMed
- [7] Christian Boggio Marzet et al.. Arch Argent Pediatr. 2022. Approach to probiotics in pediatrics: the role of Lactobacillus rhamnosus GG. doi:10.5546/aap.2022.eng.e1 PubMed
- [8] Vincent I Lau et al.. Can J Anaesth. 2022. Health economic evaluation alongside the Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial (E-PROSPECT): a cost-effectiveness analysis. doi:10.1007/s12630-022-02335-9 PubMed
- [9] Elie Akanny et al.. Int J Pharm. 2020. Development of enteric polymer-based microspheres by spray-drying for colonic delivery of Lactobacillus rhamnosus GG. doi:10.1016/j.ijpharm.2020.119414 PubMed
- [10] Mario Baù et al.. Pediatr Gastroenterol Hepatol Nutr. 2020. Risk and Protective Factors for Gastrointestinal Symptoms associated with Antibiotic Treatment in Children: A Population Study. doi:10.5223/pghn.2020.23.1.35 PubMed
- [11] Cecilia Mantegazza et al.. Pharmacol Res. 2018. Probiotics and antibiotic-associated diarrhea in children: A review and new evidence on Lactobacillus rhamnosus GG during and after antibiotic treatment. doi:10.1016/j.phrs.2017.08.001 PubMed
- [12] Valeria Agamennone et al.. BMC Gastroenterol. 2018. A practical guide for probiotics applied to the case of antibiotic-associated diarrhea in The Netherlands. doi:10.1186/s12876-018-0831-x PubMed
- [13] Jiayi Cai et al.. United European Gastroenterol J. 2018. Comparative efficacy and tolerability of probiotics for antibiotic-associated diarrhea: Systematic review with network meta-analysis. doi:10.1177/2050640617736987 PubMed
- [14] Ciro Esposito et al.. Probiotics Antimicrob Proteins. 2018. Frequency of Antibiotic-Associated Diarrhea and Related Complications in Pediatric Patients Who Underwent Hypospadias Repair: a Comparative Study Using Probiotics vs … doi:10.1007/s12602-017-9324-4 PubMed
- [15] Donald Cameron et al.. World J Gastroenterol. 2017. Probiotics for gastrointestinal disorders: Proposed recommendations for children of the Asia-Pacific region. doi:10.3748/wjg.v23.i45.7952 PubMed
- [16] Hania Szajewska et al.. J Pediatr Gastroenterol Nutr. 2016. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. doi:10.1097/MPG.0000000000001081 PubMed
- [17] Hania Szajewska et al.. Dig Dis. 2016. Probiotic Bacterial and Fungal Strains: Claims with Evidence. doi:10.1159/000443359 PubMed
- [18] Sylvia Cruchet et al.. Paediatr Drugs. 2015. The use of probiotics in pediatric gastroenterology: a review of the literature and recommendations by Latin-American experts. doi:10.1007/s40272-015-0124-6 PubMed
- [19] Alfredo Guarino et al.. J Clin Gastroenterol. 2015. Probiotics for Prevention and Treatment of Diarrhea. doi:10.1097/MCG.0000000000000349 PubMed
- [20] Danielle Barnes et al.. Nutr Clin Pract. 2015. Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children. doi:10.1177/0884533615610081 PubMed
- [21] Carlos Pérez. Nutr Hosp. 2015. [Probiotics for the treating acute diarrhea and preventing antibiotic-associated diarrhea in children]. doi:10.3305/nh.2015.31.sup1.8709 PubMed
- [22] Ewa Kamińska. Med Wieku Rozwoj. 2012. [Effectiveness and safety of probiotics in children on the basis of clinical trials]. PubMed
- [23] Alfredo Guarino et al.. Curr Opin Gastroenterol. 2009. Probiotics as prevention and treatment for diarrhea. doi:10.1097/MOG.0b013e32831b4455 PubMed
- [24] Michael de Vrese et al.. Adv Biochem Eng Biotechnol. 2008. Probiotics, prebiotics, and synbiotics. doi:10.1007/10_2008_097 PubMed
- [25] Michael de Vrese et al.. J Nutr. 2007. Probiotics and prebiotics: effects on diarrhea. doi:10.1093/jn/137.3.803S PubMed
- [26] Lynne V McFarland. Am J Gastroenterol. 2006. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. doi:10.1111/j.1572-0241.2006.00465.x PubMed
- [27] Jeffry A Katz. J Clin Gastroenterol. 2006. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea. doi:10.1097/00004836-200603000-00017 PubMed
- [28] Riku Korhonen et al.. Inflammation. 2002. Signalling mechanisms involved in the induction of inducible nitric oxide synthase by Lactobacillus rhamnosus GG, endotoxin, and lipoteichoic acid. doi:10.1023/a:1019720701230 PubMed
- [29] P R Marteau et al.. Am J Clin Nutr. 2001. Protection from gastrointestinal diseases with the use of probiotics. doi:10.1093/ajcn/73.2.430s PubMed
- [30] R Korhonen et al.. Inflammation. 2001. Induction of nitric oxide synthesis by probiotic Lactobacillus rhamnosus GG in J774 macrophages and human T84 intestinal epithelial cells. doi:10.1023/a:1010971703271 PubMed
- [31] J A Vanderhoof et al.. J Pediatr. 1999. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. doi:10.1016/s0022-3476(99)70053-3 PubMed
- [32] T Arvola et al.. Pediatrics. 1999. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. doi:10.1542/peds.104.5.e64 PubMed
Avertissement FDA: Ces déclarations n'ont pas été évaluées par la Food and Drug Administration. Les produits et informations sur ce site ne sont pas destinés à diagnostiquer, traiter, guérir ou prévenir quelque maladie que ce soit. Les notes de preuve présentées sont basées sur notre analyse de la recherche publiée et évaluée par des pairs et ne constituent pas un avis médical. Consultez toujours votre professionnel de santé avant de commencer tout régime de compléments alimentaires.